A
Ajay Bapna
Researcher at Tata Memorial Hospital
Publications - 17
Citations - 228
Ajay Bapna is an academic researcher from Tata Memorial Hospital. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 6, co-authored 13 publications receiving 203 citations.
Papers
More filters
Journal ArticleDOI
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral Talactoferrin in Combination with Carboplatin and Paclitaxel in Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer
Raghunadharao Digumarti,Yenyun Wang,Ganapathi Raman,Dinesh C. Doval,Suresh H. Advani,Pramod Kumar Julka,Purvish M. Parikh,Shekhar Patil,Shona Nag,Jayaprakash Madhavan,Ajay Bapna,Annantbhushan A. Ranade,Atul Varadhachary,Rajesh K. Malik +13 more
TL;DR: TLF, in combination with C/P, demonstrated an apparent improvement in RR, PFS, and OS in patients with previously untreated stage IIIB/IV non-small cell lung cancer and appears to enhance activity without significant additional toxicity.
Journal ArticleDOI
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Single-Agent Oral Talactoferrin in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer That Progressed After Chemotherapy
Purvish M. Parikh,Ashok K. Vaid,Suresh H. Advani,Raghunadharao Digumarti,Jayaprakash Madhavan,Shona Nag,Ajay Bapna,Jagdev S. Sekhon,Shekhar Patil,Preeti M. Ismail,Yenyun Wang,Atul Varadhachary,Junming Zhu,Rajesh K. Malik +13 more
TL;DR: TLF demonstrated an apparent improvement in OS in patients with stages IIIB to IV NSCLC for whom one or two prior lines of systemic anticancer therapy had failed and was well tolerated.
Journal ArticleDOI
Outpatient antimicrobial protocol for febrile neutropenia: a nonrandomized prospective trial using ceftriaxone, amikacin, and oral adjuvant agents.
TL;DR: It is concluded that a selected group of patients with FN can be effectively managed with this regimen on an outpatient basis by reducing the pressures of hospitalization for febrile neutropenia.
Journal ArticleDOI
All-trans-retinoic acid (ATRA): pediatric acute promyelocytic leukemia.
TL;DR: Significantly prolonged disease-free survival was seen in patients who received ATRA with chemotherapy, and ATRA was well-tolerated by these patients.
Journal ArticleDOI
Acute promyelocytic leukemia: all-trans retinoic acid (ATRA) along with chemotherapy is superior to ATRA alone.
Suresh H. Advani,Reena Nair,Ajay Bapna,B. Gladstone,Pratibha Amare Kadam,Tapan K. Saikia,Purvish M. Parekh,Ramakrishnan Gopal,Chandrica N. Nair +8 more
TL;DR: A significant improvement in the event free survival of patients receiving chemotherapy as consolidation following ATRA is shown, and the relapse‐free survival is 42% at four years for patients treated with ATRA followed by chemotherapy.